[Postoperative hormone (endocrine) therapy in endometrial carcinoma].
Hiura
Masamichi
M
Department of Gynecology and Clinical Research, National Hospital Organization Shikoku Cancer Center.
Oshita
Takafumi
T
Nogawa
Takayoshi
T
Yokoyama
Takashi
T
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D004359:Drug Therapy, Combination; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D004967:Estrogens / Q000502:physiology; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D009570:Nitriles / Q000627:therapeutic use; D011182:Postoperative Care; D013629:Tamoxifen / Q000008:administration & dosage*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004967:Estrogens; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D007987:Gonadotropin-Releasing Hormone; D017258:Medroxyprogesterone Acetate; D016729:Leuprolide